Immatics Biotechnologies has landed a potential US$1.1bn deal with GlaxoSmithKline (GSK) to find novel cancer...
OPINION
Experts Point of View
Every year, it’s the same: in January, investors are scratching their heads, searching to find investment...
While open innovation may be seen as a way of cutting costs by shutting down in-house R&D in favour of...
Spanish 3P Biopharmaceuticals has shown tremendous growth, at least 10 per cent above market growth rate in...
A newly forming industry association warns the European Commission not to block patients’ access to the...
The European biotech sector is flourishing – rising stock prices, big partnering deals, and some major M&A....
Share
